Literature DB >> 27977074

The efficacy of prazosin for the treatment of posttraumatic stress disorder nightmares in U.S. military veterans.

Annamarie Breen1, Kory Blankley1, Julie Fine1.   

Abstract

BACKGROUND AND
PURPOSE: Nightmares associated with posttraumatic stress disorder (PTSD) are a hallmark symptom among U.S. military veterans who have seen combat. Management of combat-related nightmares can be difficult and current pharmacologic options are limited and tend to have adverse side effects. The aim of this review is to explore recent literature regarding the efficacy of prazosin for the treatment of nightmare disorder in the veteran population.
METHODS: Recent literature consisting of three systematic reviews was reviewed, as well as current clinical guidelines published by The Department of Veterans Affairs (VA) and The Department of Defense (DoD) and the American Academy of Sleep Medicine (AASM).
CONCLUSIONS: Prazosin has been shown to be effective in the treatment of PTSD trauma-related nightmares. As a result of its low side effect profile and abilities to improve both sleep and reduce trauma nightmares, prazosin has been recommended as an adjunct therapy. IMPLICATIONS FOR PRACTICE: Prazosin should be initiated as an adjunctive treatment to promote sleep in those suffering from PTSD nightmares. It should be initiated at 1 mg and then titrated upward until absence or desired reduction of nightmares is achieved, with a maximum dosage recommendation of 20 mg at bedtime and 5 mg midmorning. ©2016 American Association of Nurse Practitioners.

Entities:  

Keywords:  Prazosin; nightmares; posttraumatic stress disorder (PTSD); veteran

Mesh:

Substances:

Year:  2016        PMID: 27977074     DOI: 10.1002/2327-6924.12432

Source DB:  PubMed          Journal:  J Am Assoc Nurse Pract        ISSN: 2327-6886            Impact factor:   1.165


  3 in total

1.  Demographic Variation in the Use of Prazosin for Treatment of Sleep Disturbance in Combat Veterans with PTSD.

Authors:  Miriam L Rubin; Laurel A Copeland; Aimee R Kroll-Desrosiers; Alice G Knittel
Journal:  Psychopharmacol Bull       Date:  2020-05-19

Review 2.  α 2-Adrenoceptors: Challenges and Opportunities-Enlightenment from the Kidney.

Authors:  William A Pettinger; Edwin K Jackson
Journal:  Cardiovasc Ther       Date:  2020-04-29       Impact factor: 3.023

3.  The Structural Determinants for α1-Adrenergic/Serotonin Receptors Activity among Phenylpiperazine-Hydantoin Derivatives.

Authors:  Katarzyna Kucwaj-Brysz; Anna Dela; Sabina Podlewska; Marek Bednarski; Agata Siwek; Grzegorz Satała; Kinga Czarnota; Jadwiga Handzlik; Katarzyna Kieć-Kononowicz
Journal:  Molecules       Date:  2021-11-20       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.